We are live on ! Find out more
PHAT icon

Phathom Pharmaceuticals
PHAT

110 hedge funds and large institutions have $453M invested in Phathom Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 48 increasing their positions, 24 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

395% more call options, than puts

Call options by funds: $1.61M | Put options by funds: $326K

114% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 7

100% more repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 24

7% more funds holding

Funds holding: 103 → 110 (+7)

1.11% less ownership

Funds ownership: 78.15% → 77.04% (-1.1%)

20% less funds holding in top 10

Funds holding in top 10: 5 → 4 (-1)

26% less capital invested

Capital invested by funds: $613M → $453M (-$160M)

Holders
110
Holders Change
+7
Holders Change %
+6.8%
% of All Funds
1.75%
Holding in Top 10
4
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-20%
% of All Funds
0.06%
New
15
Increased
48
Reduced
24
Closed
7
Calls
$1.61M
Puts
$326K
Net Calls
+$1.29M
Net Calls Change
-$4.25M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$5.97M
2
Citadel Advisors
Citadel Advisors
Florida
+$3.55M
3
GGHC
Gilder Gagnon Howe & Co
New York
+$3.42M
4
GTC
Ghost Tree Capital
New York
+$3.3M
5
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$2.88M

Top Sellers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
-$9.39M
2
APM
Avidity Partners Management
Texas
-$4.56M
3
TCM
Tang Capital Management
California
-$3.58M
4
SCM
Silverarc Capital Management
Massachusetts
-$2.86M
5
6CM
683 Capital Management
New York
-$2.57M
Name Holding Trade Value Shares
Change 		Change in
Stake
Northern Trust
26
Northern Trust
Illinois
$2.79M +$708K +51,590 +24%
Charles Schwab
27
Charles Schwab
California
$2.56M +$930K +67,811 +38%
SAM
28
Simplify Asset Management
Nevada
$2.47M – – –
ACM
29
Altium Capital Management
New York
$2.28M +$172K +12,568 +6%
AA
30
AlphaCentric Advisors
Puerto Rico
$1.66M +$412K +30,000 +23%
JP Morgan Chase
31
JP Morgan Chase
New York
$1.5M +$148K +10,760 +8%
Millennium Management
32
Millennium Management
New York
$1.45M +$1.53M +111,407 +399%
Goldman Sachs
33
Goldman Sachs
New York
$1.44M -$222K -16,168 -10%
D.E. Shaw & Co
34
D.E. Shaw & Co
New York
$1.35M +$231K +16,871 +15%
GCP
35
GSA Capital Partners
United Kingdom
$1.26M +$933K +67,983 +126%
UOC
36
UBS O'Connor
Illinois
$1.22M -$315K -23,000 -16%
Wellington Management Group
37
Wellington Management Group
Massachusetts
$1.04M +$24.6K +1,797 +2%
Bank of New York Mellon
38
Bank of New York Mellon
New York
$986K +$226K +16,478 +21%
AG
39
Algert Global
California
$952K +$1.26M +91,820 New
Walleye Capital
40
Walleye Capital
New York
$885K +$1.17M +85,372 New
Two Sigma Investments
41
Two Sigma Investments
New York
$872K +$584K +42,563 +103%
State of Wisconsin Investment Board
42
State of Wisconsin Investment Board
Wisconsin
$869K -$34.8K -2,539 -3%
Federated Hermes
43
Federated Hermes
Pennsylvania
$852K -$1.12M -81,808 -50%
MCM
44
Moore Capital Management
New York
$830K +$274K +20,000 +33%
Morgan Stanley
45
Morgan Stanley
New York
$811K +$80.4K +5,862 +8%
Jane Street
46
Jane Street
New York
$734K +$817K +59,584 +532%
PMAM
47
Penn Mutual Asset Management
Pennsylvania
$651K – – –
Swiss National Bank
48
Swiss National Bank
Switzerland
$624K -$155K -11,300 -16%
TI
49
Trexquant Investment
Connecticut
$610K +$556K +40,524 +221%
RhumbLine Advisers
50
RhumbLine Advisers
Massachusetts
$586K +$86.9K +6,332 +13%
1
2
3 4 5

PHAT Hedge Fund Activity: Q3 2023 in Review

110 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Phathom Pharmaceuticals (PHAT) for Q3 2023, worth a combined $453M — down 26% from $613M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new PHAT positions and 7 closed out — a net gain of 8 holders — while 48 added to existing stakes and 24 trimmed.

The largest buyer was BlackRock, adding an estimated $5.97M. The largest seller was Deerfield Management, exiting entirely with an estimated $9.39M sold.

  • 110 institutional investors held Phathom Pharmaceuticals (PHAT) as of Q3 2023, up from 103 in Q2 2023.
  • Funds reported $453M of Phathom Pharmaceuticals stock for Q3 2023, down 26% quarter-over-quarter.
  • 15 funds opened new Phathom Pharmaceuticals positions in Q3 2023 and 7 closed out, a net change of +8 holders.
  • The largest Phathom Pharmaceuticals buyer in Q3 2023 was BlackRock, an estimated $5.97M added.
  • The largest Phathom Pharmaceuticals seller in Q3 2023 was Deerfield Management, an estimated $9.39M sold.

Based on aggregated 13F filings for Q3 2023.